Nat. Biotechnol. 32, 428–435 (2014); published online 7 May 2014; corrected after print 14 May 2014
In the version of this article initially published, in Box 3, it was reported that “Catabasis will instead monitor the situation as it approaches phase 3, when large amounts of capital will be required....” The line should have read, “Catabasis instead is keeping with its plan to develop the phase 2 package for its lead program and timing a public financing with phase 3 trials....” Michael Jirousek was also incorrectly identified as founder and CEO. He is the company's co-founder and CSO.
On p. 431, column 2, Adam Cutler was incorrectly quoted as saying, “...but today, anyone 'deemed to have an exciting enough technology platform with big enough names involved, either in management or on the board or as scientific founders—that's enough to get people excited'.” It should have read, “...but in 2013 and the beginning of 2014, anyone 'deemed to have an exciting enough technology platform with big enough names involved, either in management or on the board or as scientific founders—that was enough to get people excited'.”
Additional information
The online version of the original article can be found at 10.1038/nbt.2905
Rights and permissions
About this article
Cite this article
Huggett, B. Erratum: Biotech's wellspring: the health of private biotech in 2013. Nat Biotechnol 32, 592 (2014). https://doi.org/10.1038/nbt0614-592a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0614-592a